<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03228290</url>
  </required_header>
  <id_info>
    <org_study_id>11-07513</org_study_id>
    <secondary_id>1R21AG067554</secondary_id>
    <secondary_id>R21DK127275</secondary_id>
    <nct_id>NCT03228290</nct_id>
  </id_info>
  <brief_title>Functional Assessment in Liver Transplantation</brief_title>
  <acronym>FrAILT</acronym>
  <official_title>Functional Assessment in Liver Transplant Candidates (FrAILT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective cohort study of patients with liver disease. Subjects will undergo&#xD;
      geriatric assessments of frailty, functional status, and disability using functional status&#xD;
      measures at baseline and at every clinic visit in the pre-transplant setting. Subjects will&#xD;
      also answer questions regarding quality of life, personality, and/or cognitive function.&#xD;
      Subjects will again undergo assessments at every clinic visit through 12 months after&#xD;
      transplant. Then, they will be followed annually.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be asked to perform the following study procedures:&#xD;
&#xD;
        1. Assessment of cognitive function, quality of life, and/or personality using cognitive&#xD;
           tests and questionnaires.&#xD;
&#xD;
        2. Measures of frailty and disability selected to capture the multi-dimensional aspects of&#xD;
           frailty including functional status and physiologic reserve:&#xD;
&#xD;
           Fried Frailty Score: weakness (test of grip strength), exhaustion (patient interview),&#xD;
           slowness (gait speed), low activity (patient interview) Short Physical Performance&#xD;
           Battery: repeated chair stands, balance testing with feet together, 13-foot walk&#xD;
&#xD;
        3. Laboratory tests will all be obtained from the medical record: creatinine, total&#xD;
           bilirubin, INR, sodium, albumin. All of these tests are necessary for listing for liver&#xD;
           transplantation.&#xD;
&#xD;
        4. Blood draw, urine and stool samples will be collected for a sub-group of 1000 patients.&#xD;
&#xD;
        5. Adipose, muscle, liver tissue, and blood will be collected during the liver transplant&#xD;
           surgery for a sub-group of 1000 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2011</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frailty and functional status as assessed by grip strength, chair stands, and balance which comprise the Liver Frailty Index (LFI).</measure>
    <time_frame>December 31, 2023</time_frame>
    <description>Grip strength: Performance-based. Measured in kilograms. This was measured in each subject's dominant hand using a hand dynamometer (Jamar Hydraulic hand dynamometer). We averaged three trials.&#xD;
Chair stands: Performance-based. Measured in number of chair stands per second. Number of chair stands completed in 30 seconds.&#xD;
Balance: Performance-based. Measured in seconds. Ability to balance in three positions (feet placed side to side, semitandem, and tandem) for 10 seconds each.&#xD;
Liver Frailty Index (LFI): (coefficient x grip) + (coefficient x chair stands) + (coefficient x balance) +6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine the association between frailty and outcomes both before and after liver transplantation.</measure>
    <time_frame>December 31, 2023</time_frame>
    <description>Outcomes measured prior to transplant will include: waiting for transplant, died pre-transplant, deactivated too sick, deactivated for social reasons/inactive, deferred not a candidate, and transplanted. Outcomes that will be measured post transplant include: still alive, died post transplant, and re-transplanted. All measures will be acquired via patient interview or review of medical records.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the change in frailty and physical function both before and after liver transplant or treatment utilizing the LFI.</measure>
    <time_frame>December 31, 2023</time_frame>
    <description>See outcome 1 for how LFI is measured.</description>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>End Stage Liver Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sub-group of 1000 patients will have one single blood draw of 2 tablespoons of blood and&#xD;
      provide a urine and stool sample (about 5ml each or 1 teaspoon each), at the time of consent.&#xD;
      If they agree to participate in the DNA genetic testing, then they will have an additional 1&#xD;
      tablespoon drawn during the same venipuncture.&#xD;
&#xD;
      Sub-group of 1000 patients will have adipose, muscle, liver tissue, and blood collected&#xD;
      during the liver transplant surgery.&#xD;
&#xD;
        -  8 cm³ of muscle tissue from the rectus muscle in the abdomen.&#xD;
&#xD;
        -  8 cm³ of adipose tissue from the subcutaneous and visceral adipose tissue of the&#xD;
           abdomen.&#xD;
&#xD;
        -  8 cm³ of liver tissue from the explanted liver&#xD;
&#xD;
        -  4 tablespoons of blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are being seen for the treatment of their liver disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (≥18 years old)&#xD;
&#xD;
          -  Are seen for the treatment of liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer C Lai, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer C Lai, MD, MBA</last_name>
    <phone>(415) 476-6422</phone>
    <email>jennifer.lai@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fawzy Barry, BS</last_name>
    <phone>(415) 476-6119</phone>
    <email>fawzy.barry@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer C Lai, MD, MBA</last_name>
      <phone>415-476-2777</phone>
      <email>jennifer.lai@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Fawzy Barry, BS</last_name>
      <phone>415-476-6119</phone>
      <email>fawzy.barry@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer C Lai, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Ganger, MD</last_name>
      <phone>312-695-4496</phone>
      <email>dganger@nmff.org</email>
    </contact>
    <contact_backup>
      <last_name>Dania Jahangir, BS</last_name>
      <phone>(312) 926-0658</phone>
      <email>dania.jahangir@northwestern.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorry Segev, MD</last_name>
      <phone>410-502-6115</phone>
      <email>dorry@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Ruck</last_name>
      <phone>203-536-0243</phone>
      <email>jessicaruck@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Verna, MD</last_name>
      <phone>212-305-9139</phone>
      <email>ev77@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Geena George</last_name>
      <phone>212-305-3839</phone>
      <email>gg2827@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Kappus, MD</last_name>
      <phone>804-828-8786</phone>
      <email>matthew.kappus@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adele Gaskin</last_name>
      <phone>919-684-0742</phone>
      <email>adele.gaskin@duke.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Tevar, MD</last_name>
      <email>tevara@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pam Bloomer, PA-C</last_name>
      <email>bloomerpm@upmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Health</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rahimi, MD</last_name>
      <phone>214-820-8500</phone>
      <email>Robert.Rahimi@BSWHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Hannah Amundson</last_name>
      <phone>(214) 818-7940</phone>
      <email>hannah.amundson@bswhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://liverfrailtyindex.ucsf.edu/</url>
    <description>We developed a novel clinical liver frailty index, consisting of hand grip strength, timed chair stands, and balance testing, that correctly reclassifies 1 in 5 patients to their accurate survival status, compared to MELDNa alone.</description>
  </link>
  <results_reference>
    <citation>Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant. 2014 Aug;14(8):1870-9. doi: 10.1111/ajt.12762. Epub 2014 Jun 16.</citation>
    <PMID>24935609</PMID>
  </results_reference>
  <results_reference>
    <citation>Lai JC, Covinsky KE, Hayssen H, Lizaola B, Dodge JL, Roberts JP, Terrault NA, Feng S. Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation. Liver Int. 2015 Sep;35(9):2167-73. doi: 10.1111/liv.12792. Epub 2015 Feb 12.</citation>
    <PMID>25644788</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang CW, Covinsky KE, Feng S, Hayssen H, Segev DL, Lai JC. Functional impairment in older liver transplantation candidates: From the functional assessment in liver transplantation study. Liver Transpl. 2015 Dec;21(12):1465-70. doi: 10.1002/lt.24334. Epub 2015 Nov 6.</citation>
    <PMID>26359787</PMID>
  </results_reference>
  <results_reference>
    <citation>Lai JC, Dodge JL, Sen S, Covinsky K, Feng S. Functional decline in patients with cirrhosis awaiting liver transplantation: Results from the functional assessment in liver transplantation (FrAILT) study. Hepatology. 2016 Feb;63(2):574-80. doi: 10.1002/hep.28316. Epub 2015 Dec 16.</citation>
    <PMID>26517301</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang CW, Feng S, Covinsky KE, Hayssen H, Zhou LQ, Yeh BM, Lai JC. A Comparison of Muscle Function, Mass, and Quality in Liver Transplant Candidates: Results From the Functional Assessment in Liver Transplantation Study. Transplantation. 2016 Aug;100(8):1692-8. doi: 10.1097/TP.0000000000001232.</citation>
    <PMID>27314169</PMID>
  </results_reference>
  <results_reference>
    <citation>Lai JC, Volk ML, Strasburg D, Alexander N. Performance-Based Measures Associate With Frailty in Patients With End-Stage Liver Disease. Transplantation. 2016 Dec;100(12):2656-2660. doi: 10.1097/TP.0000000000001433.</citation>
    <PMID>27495749</PMID>
  </results_reference>
  <results_reference>
    <citation>Sinclair M, Poltavskiy E, Dodge JL, Lai JC. Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. World J Gastroenterol. 2017 Feb 7;23(5):899-905. doi: 10.3748/wjg.v23.i5.899.</citation>
    <PMID>28223735</PMID>
  </results_reference>
  <verification_date>June 2023</verification_date>
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>June 5, 2023</last_update_submitted>
  <last_update_submitted_qc>June 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Liver</keyword>
  <keyword>Liver Transplant</keyword>
  <keyword>Frailty</keyword>
  <keyword>end stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03228290
org study id: 11-07513
secondary id: 1R21AG067554
secondary id: R21DK127275
nct id: NCT03228290
lead sponsor: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This will be a prospective cohort study of patients with liver disease. Subjects will undergo
      geriatric assessments of frailty, functional status, and disability using functional status
      measures at baseline and at every clinic visit in the pre-transplant setting. Subjects will
      also answer questions regarding quality of life, personality, and/or cognitive function.
      Subjects will again undergo assessments at every clinic visit through 12 months after
      transplant. Then, they will be followed annually.
Patients will be asked to perform the following study procedures:

        1. Assessment of cognitive function, quality of life, and/or personality using cognitive
           tests and questionnaires.

        2. Measures of frailty and disability selected to capture the multi-dimensional aspects of
           frailty including functional status and physiologic reserve:

           Fried Frailty Score: weakness (test of grip strength), exhaustion (patient interview),
           slowness (gait speed), low activity (patient interview) Short Physical Performance
           Battery: repeated chair stands, balance testing with feet together, 13-foot walk

        3. Laboratory tests will all be obtained from the medical record: creatinine, total
           bilirubin, INR, sodium, albumin. All of these tests are necessary for listing for liver
           transplantation.

        4. Blood draw, urine and stool samples will be collected for a sub-group of 1000 patients.

        5. Adipose, muscle, liver tissue, and blood will be collected during the liver transplant
           surgery for a sub-group of 1000 patients.
observational model: Cohort
time perspective: Prospective
measure: Frailty and functional status as assessed by grip strength, chair stands, and balance which comprise the Liver Frailty Index (LFI).
time frame: December 31, 2023
description: Grip strength: Performance-based. Measured in kilograms. This was measured in each subject's dominant hand using a hand dynamometer (Jamar Hydraulic hand dynamometer). We averaged three trials.
Chair stands: Performance-based. Measured in number of chair stands per second. Number of chair stands completed in 30 seconds.
Balance: Performance-based. Measured in seconds. Ability to balance in three positions (feet placed side to side, semitandem, and tandem) for 10 seconds each.
Liver Frailty Index (LFI): (coefficient x grip) + (coefficient x chair stands) + (coefficient x balance) +6
measure: Examine the association between frailty and outcomes both before and after liver transplantation.
time frame: December 31, 2023
description: Outcomes measured prior to transplant will include: waiting for transplant, died pre-transplant, deactivated too sick, deactivated for social reasons/inactive, deferred not a candidate, and transplanted. Outcomes that will be measured post transplant include: still alive, died post transplant, and re-transplanted. All measures will be acquired via patient interview or review of medical records.
measure: Evaluate the change in frailty and physical function both before and after liver transplant or treatment utilizing the LFI.
time frame: December 31, 2023
description: See outcome 1 for how LFI is measured.
Sub-group of 1000 patients will have one single blood draw of 2 tablespoons of blood and
      provide a urine and stool sample (about 5ml each or 1 teaspoon each), at the time of consent.
      If they agree to participate in the DNA genetic testing, then they will have an additional 1
      tablespoon drawn during the same venipuncture.

      Sub-group of 1000 patients will have adipose, muscle, liver tissue, and blood collected
      during the liver transplant surgery.

        -  8 cm³ of muscle tissue from the rectus muscle in the abdomen.

        -  8 cm³ of adipose tissue from the subcutaneous and visceral adipose tissue of the
           abdomen.

        -  8 cm³ of liver tissue from the explanted liver

        -  4 tablespoons of blood
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Jennifer C Lai, MD, MBA
role: Principal Investigator
affiliation: University of California, San Francisco
last name: Jennifer C Lai, MD, MBA
phone: (415) 476-6422
email: jennifer.lai@ucsf.edu
last name: Fawzy Barry, BS
phone: (415) 476-6119
email: fawzy.barry@ucsf.edu
facility: 
status: Completed
facility: 
status: Completed
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
facility: 
status: Recruiting
contact: 
contact backup: 
facility: 
status: Active, not recruiting
facility: 
status: Recruiting
contact: 
contact backup: 
facility: 
status: Recruiting
contact: 
contact backup: 
facility: 
status: Recruiting
contact: 
contact backup: 
facility: 
status: Recruiting
contact: 
contact backup: 
facility: 
status: Active, not recruiting
country: United States
url: http://liverfrailtyindex.ucsf.edu/
description: We developed a novel clinical liver frailty index, consisting of hand grip strength, timed chair stands, and balance testing, that correctly reclassifies 1 in 5 patients to their accurate survival status, compared to MELDNa alone.
citation: Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant. 2014 Aug;14(8):1870-9. doi: 10.1111/ajt.12762. Epub 2014 Jun 16.
PMID: 24935609
citation: Lai JC, Covinsky KE, Hayssen H, Lizaola B, Dodge JL, Roberts JP, Terrault NA, Feng S. Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation. Liver Int. 2015 Sep;35(9):2167-73. doi: 10.1111/liv.12792. Epub 2015 Feb 12.
PMID: 25644788
citation: Wang CW, Covinsky KE, Feng S, Hayssen H, Segev DL, Lai JC. Functional impairment in older liver transplantation candidates: From the functional assessment in liver transplantation study. Liver Transpl. 2015 Dec;21(12):1465-70. doi: 10.1002/lt.24334. Epub 2015 Nov 6.
PMID: 26359787
citation: Lai JC, Dodge JL, Sen S, Covinsky K, Feng S. Functional decline in patients with cirrhosis awaiting liver transplantation: Results from the functional assessment in liver transplantation (FrAILT) study. Hepatology. 2016 Feb;63(2):574-80. doi: 10.1002/hep.28316. Epub 2015 Dec 16.
PMID: 26517301
citation: Wang CW, Feng S, Covinsky KE, Hayssen H, Zhou LQ, Yeh BM, Lai JC. A Comparison of Muscle Function, Mass, and Quality in Liver Transplant Candidates: Results From the Functional Assessment in Liver Transplantation Study. Transplantation. 2016 Aug;100(8):1692-8. doi: 10.1097/TP.0000000000001232.
PMID: 27314169
citation: Lai JC, Volk ML, Strasburg D, Alexander N. Performance-Based Measures Associate With Frailty in Patients With End-Stage Liver Disease. Transplantation. 2016 Dec;100(12):2656-2660. doi: 10.1097/TP.0000000000001433.
PMID: 27495749
citation: Sinclair M, Poltavskiy E, Dodge JL, Lai JC. Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. World J Gastroenterol. 2017 Feb 7;23(5):899-905. doi: 10.3748/wjg.v23.i5.899.
PMID: 28223735
responsible party type: Sponsor
mesh term: Liver Diseases
mesh term: End Stage Liver Disease
sharing ipd: No